$541.5 million. One Florida health system. Four years of fake diagnosis codes. 🚨 This week the DOJ announced that The Villages Health, a Central Florida provider serving one of the world's largest retirement communities, agreed to pay $541.5 million to settle allegations it overbilled Medicare Advantage from 2020 to 2024. Here is how it worked. Under Medicare Advantage, the government pays insurers a fixed monthly amount per member. That payment adjusts upward for sicker patients. CMS calculates the adjustment using medical diagnosis codes submitted by providers. A more severe diagnosis means a higher risk score, which means more money. The Villages Health allegedly submitted false diagnosis codes to its MA insurers to inflate those risk scores and collect higher reimbursement. ...

Everyone says the FDA is moving too slow on AI. They're wrong. 🧠 Moving fast on a broken framework would be worse than moving carefully on the right one. This week, the FDA's Digital Health Center of Excellence released a discussion paper on regulating generative AI-enabled medical devices, opened under docket FDA-2026-N-7874, with public comments due October 19, 2026. According to Edge RCM, which broke down the development for physicians, this is the agency's first real attempt at a framework built specifically for GenAI devices, rather than stretching existing software and AI/ML rules to cover them. That distinction matters more than most people realize. The old FDA frameworks assumed three things: - Inputs are bounded - Outputs are fixed - ...

$116 million. And a full acquisition on the same day. 🔥 That is not a funding round. That is a statement. According to StartUp Health, Cityblock Health closed a $116M Series E led by General Catalyst this week, pushing its total funding to more than $900M. Simultaneously, the Brooklyn-based value-based care company signed a definitive agreement to acquire Homeward Health in an all-stock transaction. Let that sink in. Most companies celebrate a round. Cityblock used their raise to also buy a company. Here is why this matters right now: - Cityblock built its reputation serving urban Medicaid and dual-eligible populations - Homeward Health brings rural Medicare Advantage reach - Together, they are targeting 120 million Americans who depend on Medicaid ...

FDA clearance is not the finish line for AI radiology tools. 🚩 It is just stage two of a four-stage ladder most hospitals have never mapped out. CMS just approved a New Technology Add-on Payment for Aidoc's CARE Body CT Multi-Triage, effective October 1, 2026. According to EHRAtlas, the NTAP provides a three-year reimbursement pathway for qualifying Medicare Fee-for-Service inpatient cases. That is a landmark moment. And it exposed exactly how broken most hospitals' AI evaluation process is. Here is the framework I call The AI Radiology Reimbursement Ladder. 🔷 Stage 1: Regulatory Foundation The tool must receive FDA Breakthrough Device Designation before clearance. For CARE Body CT Multi-Triage, the FDA granted Breakthrough Device Designation in September 2025. Full clearance ...

5:00 p.m. Monday. The clock ran out on the biggest drug pricing fight in years. Over 11,000 public comments landed in the docket for CMS-4215-P, according to Latham and Watkins' Drug Pricing Digest. The comment window closed August 17, 2026. This was not just another regulatory notice. According to PharmaDossier, CMS-4215-P is the agency's first comprehensive notice-and-comment rulemaking to formally codify the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act of 2022 into binding federal regulations. For the first three negotiated cycles, IPAY 2026, IPAY 2027, and IPAY 2028, CMS ran the entire program through sub-regulatory guidance. No APA rulemaking. No formal public comment. No judicial review under the arbitrary-and-capricious standard. That era is now over. 🔍 ...

The cancer cure hiding in plain sight is not a drug. 🔬 It is a free at-home test that takes minutes to complete. According to ScienceDaily, a new study published in JAMA Network Open by researchers at Karolinska Institutet and Umeå University found that people who participated in colorectal cancer screening had a 43% lower risk of dying from the disease. The study tracked 376,511 people for up to 14 years through the Stockholm-Gotland screening program. That is not a small signal. That is one of the most compelling cancer survival findings of the year. Here is what the numbers actually show: - Receiving an invitation to screening alone was linked to a 26% lower risk of dying from colorectal ...

Everyone thinks MSK software is boring. Flagler Health just proved it isn't. 🔥 The conventional take on musculoskeletal health tech is that it's a sleepy, commoditized corner of the market. Scheduling tools, basic EMR plugins, nothing worth getting excited about. That take is wrong. Flagler Health just closed a $50 million Series B, bringing its total raised to $63 million. And the people who wrote the checks are not exactly known for backing boring companies. 💡 Who they are: Flagler Health is an AI-native platform that coordinates clinical and administrative workflows for musculoskeletal healthcare providers. Think orthopedics, physical therapy, spine care. They plug directly into providers' existing EMRs, which means no rip-and-replace, no massive implementation project, no reason to say ...

Everyone is celebrating the SAFFRON trial. I want to slow down. 🧬 The headlines are right that this is significant. But the most important thing SAFFRON gives us is not a drug combination. It is a decision framework for what to do BEFORE you ever reach for a salvage regimen. Here is how I think thoracic tumor boards should use this data. --- THE SAFFRON RESISTANCE EVALUATION FRAMEWORK For EGFR-mutated NSCLC progressing on osimertinib 1. CONFIRM THE RESISTANCE MECHANISM FIRST SAFFRON required prospective eligibility based on high MET overexpression and/or amplification, determined by IHC for protein expression and FISH for gene amplification, according to Pharmacy Times. That is not optional context. That is the protocol. Molecular testing at progression is ...

The radiology workforce story everyone is telling is the wrong one. 🩻 The dominant narrative is simple: we have a shortage, so we need more radiologists. Hire more, read more, fix it. But a new Medscape survey published August 14, 2026 tells a different story. According to xAID, 42% of the roughly 177 millennial radiologists surveyed said their compensation was flat (33%) or had actually fallen (9%) over the past year. Fifty-eight percent saw an increase. In a specialty supposedly starved for talent, nearly half of the youngest cohort is going nowhere on pay. Hiring does not fix that. And here is why. 📌 Introducing the 4-Force Radiology Revenue Squeeze This is the framework I use to explain why per-study ...